Jörg Elliesen

Title: Jörg Elliesen: Innovator in Hormone Replacement Therapy

Introduction

Jörg Elliesen is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of medicine, particularly in hormone replacement therapy. With a total of 2 patents, his work focuses on innovative solutions for treating androgen deficiency in men.

Latest Patents

Elliesen's latest patents include a combination of dehydroepiandrosterone (DHEA) and aromatase inhibitors. This combination is used to produce a medicament for treating relative and absolute androgen deficiency in men. The invention emphasizes the use of selective aromatase inhibitors such as atamestan, formestan, pentrozol, aramidex, fadrozol, CGS 20267, and vorozol. Another significant patent involves a hormone replacement therapy method that allows for varying the daily dose of estrogen and progestogen. This method facilitates optimal compliance by enabling adjustments without the need for a new prescription each time the dosage changes.

Career Highlights

Jörg Elliesen is associated with Schering Aktiengesellschaft, a company known for its advancements in pharmaceuticals. His work has contributed to the development of effective treatments in hormone therapy, showcasing his expertise and dedication to medical innovation.

Collaborations

Elliesen has collaborated with notable coworkers, including Jutta Riedl and Albert Radlmaier. Their combined efforts have furthered research and development in the field of hormone replacement therapy.

Conclusion

Jörg Elliesen's contributions to medicine through his patents and work at Schering Aktiengesellschaft highlight his role as an innovator in hormone replacement therapy. His inventions continue to impact the treatment of androgen deficiency in men, showcasing the importance of innovation in healthcare.